Intellia Therapeutics Inc. announced longer-term clinical data from a pooled Phase 1/2 analysis of lonvoguran ziclumeran (lonvo-z; NTLA-2002) 50 mg in patients with hereditary angioedema. The company reported that, across 32 patients with up to three years of follow-up, mean monthly attack rates were consistently 0.2 or lower, corresponding to a 96% mean reduction in attacks from baseline through last follow-up, and 31 of 32 patients were attack-free and not using long-term prophylaxis at the data cutoff. The results were presented as poster data at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intellia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603030730PRIMZONEFULLFEED9664200) on March 03, 2026, and is solely responsible for the information contained therein.